9-cis-Retinoic acid (ALRT1057), a derivative of vitamin A, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates the cell cycle and has anticancer, anti-inflammatory and neuroprotective activities.
|Solubility (25°C)||DMSO : 25 mg/mL|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Gene K Lee, et al. Lymphat Res Biol. Prolymphangiogenic Effects of 9- cis Retinoic Acid Are Enhanced at Sites of Lymphatic Injury and Dependent on Treatment Duration in Experimental Postsurgical Lymphedema
|Related RAR/RXR Products|
KCL-286 is an orally active retinoic acid receptor-beta (RAR-beta) agonist for studies related to spinal cord injury.
XS-060 is a potent anticancer agent and RXRα antagonist.
BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction.
|ER 50891 quarterhydrate
ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα).
4-Hydroxyretinoic acid (4-HRA) is a naturally occurring retinoid derivative with diverse biological effects.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.